Saltar al contenido
Merck

Documentos clave

Ver Toda la documentación

45706

Warfarina

PESTANAL®, analytical standard

Sinónimos:

4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin, Coumafene

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):
C19H16O4
Número CAS:
81-81-2
Peso molecular:
308.33
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329756915
EC Number:
201-377-6
Beilstein/REAXYS Number:
8868198
MDL number:
MFCD00006854
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle

grade

analytical standard

Quality Level

100

product line

PESTANAL®

shelf life

limited shelf life, expiry date on the label

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

mp

162-164 °C (lit.)

application(s)

agriculture
environmental

format

neat

SMILES string

CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O

InChI

1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

InChI key

PJVWKTKQMONHTI-UHFFFAOYSA-N

Gene Information

human ... VKORC1(79001)

Application

Warfarin is an anticoagulant commonly used in the prevention of thrombosis and thromboembolism. Its use is studied in stroke and pulmonary fibrosis patients among many others. It is used to study potential risks and interactions with other drugs and food.
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Biochem/physiol Actions

Warfarin consists of a racemic mixture of two active enantiomers, R- and S- forms. Warfarin is slower-acting than the common anticoagulant heparin. Warfarin inhibits the vitamin K-dependent synthesis of biologically active forms of the calcium-dependent clotting factors II, VII, IX and X. It inhibits regulatory factors protein C, protein S, and protein Z.

Legal Information

PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Restringido a usuarios profesionales. Atención − Evitar exposición − obtener instrucciones especiales antes de usar

Still not finding the right product?

Explore all of our products under Warfarina

signalword

Danger

Hazard Classifications

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral

target_organs

Blood

Clase de almacenamiento

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
BCCM4467
BCCH4004
BCBV7416
BCBV3285

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Jack Ansell et al.
Chest, 126(3 Suppl), 204S-233S (2004-09-24)
This article concerning the pharmacokinetics and pharmacodynamics of vitamin K antagonists (VKAs) is part of the Seventh American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. The article describes the antithrombotic effect of VKAs, the monitoring
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Imre Noth, Kevin J. Anstrom, et al.
American Journal of Respiratory and Critical Care Medicine, 10.1164, 201202-03140C-201202-03140C (2012)
Periprocedural management of new oral anticoagulants in patients undergoing atrial fibrillation ablation.
Jeffrey I Weitz et al.
Circulation, 129(16), 1688-1694 (2014-04-23)
Ver todos los artículos relacionados